NCOG-31. GIANT PITUITARY ADENOMA (GPA) SCORE: A NOVEL SCORING SYSTEM TO PREDICT POSTOPERATIVE OUTCOMES OF GIANT PITUITARY ADENOMAS

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi158-vi158
Author(s):  
Syed Ather Enam ◽  
Fauzan Alam Hashmi ◽  
Sanam Mir Ghazi ◽  
Ahsan Ali Khan ◽  
Muhammad Bilal Tariq ◽  
...  
Keyword(s):  
Pituitary Adenoma ◽  
Linear Regression ◽  
Pituitary Adenomas ◽  
Scoring System ◽  
Tumor Resection ◽  
Maximum Diameter ◽  
Giant Pituitary Adenoma ◽  
Giant Pituitary Adenomas ◽  
The Mean ◽  
Suprasellar Extension

Abstract BACKGROUND Giant pituitary adenomas (GPA) are uncommon and highly variable in morphology and extension. There is no scoring system that considers all the dimensions of adenoma invasion. We developed a new Giant Pituitary Adenoma score and report our surgical experience and evaluate outcomes after resection of these tumors in accordance with the preoperative score. METHODS We developed a novel scoring system for classifying giant pituitary adenomas, and 11-year data of GPA surgery at our center was collected retrospectively, based on this scoring system. GPA Score considered tumor’s parasellar extension, encasement of cavernous internal carotid artery (ICA), suprasellar extension > 2 cm, suprasellar extension > 4cm and retrosellar extension. Maximum possible score was 9. The scoring system was applied to 53 patients of GPA who underwent surgical resection between January 1, 2006, and December 2017. The Lundin-Pederson (ABC/2) method was used to calculate the tumor volume both pre- and post-resection and linear regression was used to assess the relationship between extent of tumor resection and GPA score. RESULTS The median age of the study population was 42.08 ± 16.49 years. The mean maximum diameter of the pituitary adenomas was 5.0 cm (range 4.0 cm-8.5cm) while the mean volume of the adenomas was 27.3 cm3 (range 10 cm3-149 cm3). There were 3 cases of score 2, 5 cases of score 3, 13 cases of score 4, 20 cases of score 5, 9 cases of score 6 and 3 cases of score 7. The range of tumor volumes of tumors for scores from 2-7 was 17.3 cm3 to 65.8 cm3 and GPA score was correlated with the percent residual tumor using linear regression that was statistically significant (p= 0.001). CONCLUSION GPA Score is a reliable scoring system to predict the extent and subsequent difficulty in tumor resection in GPA.

scholarly journals A Unilateral Nasal Mass With Generalized Seizures: Potential Diagnostic Pitfalls in Giant Pituitary Adenoma

2019 ◽  
Vol 10 ◽  
pp. 215265671989658
Author(s):  
Rahimah Aini ◽  
Ida Sadja’ah Sachlin ◽  
Lai Chuang Chee ◽  
Baharudin Abdullah
Keyword(s):  
Pituitary Adenoma ◽  
Pituitary Adenomas ◽  
Histopathological Examination ◽  
Olfactory Neuroblastoma ◽  
Intracranial Extension ◽  
Medial Temporal Lobes ◽  
Nasal Mass ◽  
Giant Pituitary Adenoma ◽  
Generalized Seizures ◽  
Giant Pituitary Adenomas

Giant pituitary adenomas are clinically nonfunctioning adenomas, and the clinical presentation is usually secondary to compression of the neighboring structures. Visual impairment and visual field defect are the most common preoperative symptoms, followed by headache. Generalized seizures may occur in giant pituitary adenomas when there is involvement of frontal lobes or medial temporal lobes. We present a case of a unilateral nasal mass with generalized seizures in a 55-year-old woman without prior episode of seizure and any predisposing factors. Imaging showed a sinonasal tumor with intracranial extension and histopathological examination confirmed a corticotroph adenoma. On seeing a patient with a unilateral nasal mass extending down from the roof of nasal cavity, olfactory neuroblastoma, or meningo-encephalocoele readily comes to mind. To avoid misdiagnosis and delay in treatment, imaging and, if possible, a biopsy should be considered. Giant pituitary adenoma although not common should be thought of as one of the differential diagnosis.

scholarly journals Pituitary Adenomas: Presentations and Outcomes in a South Asian Country

2008 ◽  
Vol 35 (2) ◽  
pp. 198-203 ◽  
Author(s):  
Muhammad Shahzad Shamim ◽  
Muhammad Ehsan Bari ◽  
Faraz Khursheed ◽  
Rashid Jooma ◽  
Syed Ather Enam
Keyword(s):  
Pituitary Adenoma ◽  
Pituitary Adenomas ◽  
Hormone Replacement ◽  
Tumor Resection ◽  
Residual Tumor ◽  
Asian Country ◽  
Developed Countries ◽  
P Value ◽  
Tumor Diameter ◽  
Giant Pituitary Adenoma

Objective:: The purpose of this retrospective review of all operated cases of pituitary adenomas in the last decade, is to define the demographic patterns and characteristics of such tumors and to assess surgical outcomes with regards to safety and efficacy of trans–sphenoidal tumor removal in our institution.Methods:Surgically treated pituitary adenomas presenting from 1995 till 2005 were reviewed for different variables. Results were expressed as mean, standard deviation and median for continuous and number with percentage for categorical data. Chi square test was applied to measure differences and significance was taken at p value < 0.05.Results:One hundred and twenty–five patients were operated for pituitary adenoma. Sixty–three percent were male and mean age was 37 years. Sixty percent of the patients presented with headache and/or visual symptoms. Twelve percent presented with pituitary apoplexy and 28% presented with symptoms due to pituitary hyperfunction. Fifty–five percent of patients had functioning and 44% had nonfunctioning adenomas. Mean pre operative tumor diameter from 86 pre op MRI scans was 26.76 mm (3–78 mm). Eighty–four percent of patients underwent trans–sphenoidal tumor resection and three percent had craniotomy. Mean size of post op residual tumor as calculated from 76 available post operative scans was 5.3 mm (range 0–31 mm). 17.6% of the patients required hormone replacement beyond three months and 10% were re–operated. Overall mortality was 1.6%.Conclusion:In Pakistan, patients are more likely to present either with apoplexy or with a giant pituitary adenoma than patients reported from developed countries. Overall, our results have been satisfactory and comparable with the literature.

SURGICAL TREATMENT OF GIANT PITUITARY ADENOMAS

Neurosurgery ◽  
2007 ◽  
Vol 60 (6) ◽  
pp. 993-1004 ◽  
Author(s):  
Pietro Mortini ◽  
Raffaella Barzaghi ◽  
Marco Losa ◽  
Nicola Boari ◽  
Massimo Giovanelli
Keyword(s):  
Tumor Growth ◽  
Pituitary Adenomas ◽  
Protective Role ◽  
Maximum Diameter ◽  
Surgical Removal ◽  
Consecutive Series ◽  
Nonfunctioning Pituitary Adenomas ◽  
Reduce Tumor Volume ◽  
Giant Pituitary Adenomas ◽  
The Mean

Abstract OBJECTIVE Giant pituitary adenomas, defined as those measuring at least 4 cm in maximum diameter, are a therapeutic challenge. We report our experience in a large, consecutive series of patients with giant adenomas. METHODS Between 1990 and 2004, 95 patients with a giant pituitary adenomas underwent surgery at our department. Nonfunctioning pituitary adenoma was the most frequent type (n = 70; 73.7%), whereas hormone-secreting adenomas numbered only 25 (26.3%). The mean age at the time of surgery (±standard error of the mean) was 48.4 ± 1.5 years; there were 66 men (69.5%) and 29 women (20.5%). RESULTS In total, 111 surgical procedures were performed. Of these, 85 approaches (76.6%) were transsphenoidal and 26 (23.4%) were transcranial. Visual improvement occurred in 59 of the 79 patients with preoperative defect who could be evaluated after surgery (74.7%). Radical tumor excision was obtained in 14 patients (14.7%). Adjuvant medical and radiation therapies led to 74.5% (95% confidence interval, 62.7–86.4%) control of tumor growth at 5 years. This was not different in patients with nonfunctioning pituitary adenomas compared with patients with hormone-secreting tumors. In the subgroup of patients with nonfunctioning pituitary adenomas, radiation therapy had a protective role against tumor growth (P &lt; 0.01). CONCLUSION Maximal surgical removal of giant adenomas through the transsphenoidal or transcranial approach, or both, aimed to relieve compression of the optic pathway and reduce tumor volume as much as possible, offers the best chances to control the tumor when followed with adjuvant medical and radiation therapies.

Evaluation of Complications and Costs During Overlapping Transsphenoidal Surgery in the Treatment of Pituitary Adenoma

Neurosurgery ◽  
2018 ◽  
Vol 84 (5) ◽  
pp. 1104-1111 ◽  
Author(s):  
Michael Karsy ◽  
Christian A Bowers ◽  
Jonathan Scoville ◽  
Bornali Kundu ◽  
Mohammed A Azab ◽  
...  
Keyword(s):  
Pituitary Adenoma ◽  
Pituitary Adenomas ◽  
Improve Patient Safety ◽  
Surgical Complication ◽  
Tumor Resection ◽  
Healthcare Delivery ◽  
Complication Rates ◽  
Tumor Type ◽  
Presenting Symptoms ◽  
Transsphenoidal Resection

Abstract BACKGROUND Pituitary adenomas are among the most common primary brain tumors. Recently, overlapping surgery has been curbed in many institutions because of the suggestion there might be more significant adverse events, despite several studies showing that complication rates are equivalent. OBJECTIVE To assess complications and costs associated with overlapping surgery during the transsphenoidal resection of pituitary adenomas. METHODS A single-center, retrospective cohort study was performed to evaluate the cases of patients who underwent a transsphenoidal approach for pituitary tumor resection. Patient, surgical, complication, and cost (value-driven outcome) variables were analyzed. RESULTS A total of 629 patients (302 nonoverlapping, 327 overlapping cases) were identified. No significant differences in age (P = .6), sex (P = .5), tumor type (P = .5), or prior rates of pituitary adenoma resection (P = .5) were seen. Similar presenting symptoms were observed in the 2 groups, and follow-up length was comparable (P = .3). No differences in tumor sizes (P = .5), operative time (P = .4), fat/fascia use (P = .4), or cerebrospinal fluid diversion (P = .8) were seen between groups. The gross total resection rate was not significantly different (P = .9), and no difference in recurrence rate was seen (P = .4). A comparable complication rate was seen between groups (P = .6). No differences in total or subtotal costs were seen either. CONCLUSION The results of this study offer additional evidence that overlapping surgery does not result in worsened complications, lengthened surgery, or increased patient cost for patients undergoing transsphenoidal resection of pituitary adenomas. Thus, studies and policy aiming to improve patient safety and cost should focus on optimizing other aspects of healthcare delivery.

scholarly journals MON-303 Giant Growth Hormone Secreting Pituitary Adenomas: A Single Institution Case Series

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Bahadir Koylu ◽  
Suleyman Nahit Sendur ◽  
Seda Hanife Oguz ◽  
Selcuk Dagdelen ◽  
Tomris A Erbas
Keyword(s):  
Growth Hormone ◽  
Pituitary Adenoma ◽  
Pituitary Adenomas ◽  
Postoperative Radiotherapy ◽  
Somatostatin Receptor ◽  
Case Series ◽  
Tumor Diameter ◽  
Somatostatin Receptor Ligands ◽  
The Mean

Abstract The prevalence of growth hormone (GH)-secreting pituitary adenoma is around 11-13% of all pituitary adenomas. Giant GH-secreting pituitary adenomas (≥ 4 cm) are rare tumors, and its prevalence of among acromegalic patients is &lt;5%. This is a retrospective cohort study including patients with giant GH-secreting pituitary adenomas. The study population consisted of 10 patients (5 M/5 F). The mean age at diagnosis was 33.0±12.9 yrs (11-55 yrs). The mean delay between first symptom onset and diagnosis was 2.9 years. The most frequent symptoms were acral enlargement and facial changes (80%), followed by headache (70%) and visual deterioration (50%). One patient had epilepsy. Amenorrhea was presented in three females but obvious galactorrhea in two. The mean adenoma diameter was 42.6±4.7 mm (40-51 mm) at diagnosis. The vast majority of adenomas presented suprasellar extension (100%) or cavernous sinus invasion (80%). Cystic adenomas accounted for 50%. At presentation, mean GH and IGF-1 levels were 40.0±21.4 ng/mL (14.8-51.0) and 2.62±1.09 x ULN (1.08-3.96), respectively. Six patients presented with PRL cosecretion. At diagnosis maximal tumor diameter was not correlated with GH or IGF-1 levels. All patients underwent pituitary surgery as first-line treatment. Three cases were treated with an endoscopic approach and four cases with a microscopic approach. Transcranial approach was also employed in three cases. Postoperative mean GH and IGF-1 levels were 14.9±16.1 ng/mL (0.6-51.0) and 2.25.±0.82 x ULN (1.48-3.74), respectively. After first surgery, only one patient had more than 50% reduction in IGF-1 levels. Five patients (50%) underwent repeat surgery on two to three procedures because remission was not achieved. Postoperative somatostatin receptor ligands (SRLs) were used by all patients. Six patients were treated with dopamine agonist in combination with SRL. Six patients (60%) received postoperative radiotherapy. The mean follow-up period was 12.6±5.3 yrs (4-21 yrs). The mean GH and IGF-1 levels were 1.47±1.54 ng/mL (0.08-5.25) and 0.73±0.44 x ULN (0.08-1.56), respectively at the last visit. Residual adenoma was present at the last MRI in eight patients (mean diameter 9.0±3.6 mm). Panhypopituitarism rose from 10% at baseline to 30% at the last visit. During follow-up, one patient diagnosed breast cancer, while another diagnosed thyroid papillary cancer. Giant GH-secreting pituitary adenomas can have a clinically aggressive behavior with mass effect. Moreover, treatment in patients with giant GH-secreting pituitary adenoma is complex and multimodal therapy is necessary.

scholarly journals Endonasal Endoscopic Surgery for Macroadenomas: New Understanding of Pseudocapsules

2021 ◽  
Author(s):  
Zhuqing Wu ◽  
Jiang Xu ◽  
Zijian Zheng ◽  
Yunzhi Ai ◽  
Meihua Li ◽  
...  
Keyword(s):  
Pituitary Adenomas ◽  
Remission Rate ◽  
Tumor Resection ◽  
Maximum Diameter ◽  
Cerebrospinal Fluid Leakage ◽  
En Bloc ◽  
Endoscopic Endonasal ◽  
Pituitary Dysfunction ◽  
Piecemeal Resection ◽  
Extracapsular Resection

Abstract PurposeExtracapsular resection of pituitary microadenomas has been widely reported, but only a few studies have carried out further investigations in macroadenomas, especially using the endonasal endoscopic approach. The authors of this study combined not only the interoperative characteristics of pituitary adenomas and pseudocapsules but also the surgical technique, outcomes and complications in macroadenomas to investigate the pseudocapsule.MethodsIn total, 143 consecutive patients with pituitary adenomas (maximum diameter 15 - 40 mm) who underwent endoscopic endonasal-transsphenoidal surgery between January 1, 2017, and August 1, 2019, were included in the study. ResultsAmong 143 patients, 48 patients had an intact pseudocapsule, 56 patients possessed an incomplete pseudocapsule and the remaining 38 patients had no pseudocapsule. A white and thick pseudocapsule was more frequent (p=0.016) in fibrous adenomas, but tumor fibrosis (p=0.004) and adenoma apoplexy (p<0.001) were the factors that predicted the pseudocapsular integrity and hindered en bloc extracapsular resection according to a logistic regression analysis. In addition, the adenoma size (p=0.185) did not influence pseudocapsular integrity. Partial capsulectomy for macroadenomas did not show a significant advantage over piecemeal resection in gross total tumor resection (GTR) or biochemical remission (p=0.731 and p=0.685, respectively), but GTR in whole capsular resection was 100%. Additionally, this resection method had a higher risk of intraoperative cerebrospinal fluid leakage (p=0.010) and a lower incidence of new hormone deficit (p=0.043) than piecemeal resection.ConclusionsThe pseudocapsule widely exists in pituitary macroadenomas and extracapsular resection can improve GTR and hormone remission rate and reduce the occurrence of postoperative pituitary dysfunction in short-time.

scholarly journals Transcranial versus Endoscopic Transsphenoidal Approaches in Management of Recurrent Giant Pituitary Adenomas

2020 ◽  
Vol 8 (B) ◽  
pp. 273-280
Author(s):  
Mohamed Ismail ◽  
Omar Abdel Aleem Abdel Moneim Ragab ◽  
Mohamed M. Salama ◽  
Basim M. Ayoub ◽  
Wael Elmahdy
Keyword(s):  
Clinical Outcome ◽  
Pituitary Adenomas ◽  
Tumor Resection ◽  
Transsphenoidal Approach ◽  
Subtotal Resection ◽  
Visual Improvement ◽  
Group A ◽  
Transcranial Approach ◽  
Giant Pituitary Adenomas ◽  
Group B

AIM: The aim of this study was to compare the transcranial and the endoscopic transsphenoidal approaches for patients with recurrent giant pituitary adenomas as regards the extent of tumor resection and the clinical outcome. METHODS: The study included 21 patients with recurrent giant pituitary adenomas divided into two groups; Group A included nine patients operated on by transcranial approaches and Group B included 12 patients operated on by the endoscopic transsphenoidal approach. Both groups were compared as regards the extent of tumor resection and the post-operative clinical outcome, particularly the visual and endocrinological outcomes, in addition to morbidity and mortality. RESULTS: There was a higher incidence of total and near-total resection in Group B (41.7%) and a higher incidence of subtotal resection in Group A (55.6%). The incidence of visual improvement was higher in Group B (55.6%) than in Group A (28.6%). Post-operative biochemical remission was achieved in 100% of Group B patients and in 50% of Group A patients with functioning adenomas. The incidence of post-operative complications was higher in Group A (77.8%) than in Group B (50%). CONCLUSION: The endoscopic transsphenoidal approach for recurrent giant pituitary adenomas is associated with a higher extent of tumor resection, better rates of visual improvement and endocrinological remission, and lower incidence of complications. The transcranial approach should be reserved for some adenomas with marked lateral or anterior extensions, fibrous tumors, and after the failure of the endoscopic transsphenoidal approach.

NCOG-32. PROGNOSTIC IMPLICATIONS OF SIZE OF PITUITARY MACROADENOMAS: A COMPARATIVE ANALYSIS OF GIANT ADENOMAS WITH NON-GIANT MACROADENOMAS

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi158-vi159
Author(s):  
Sanam Mir Ghazi ◽  
Muhammad Bilal Tariq ◽  
Fauzan Alam Hashmi ◽  
Asra Tanwir ◽  
Ahsan Ali Khan ◽  
...  
Keyword(s):  
Tumor Resection ◽  
Extent Of Resection ◽  
Visual Field Defects ◽  
Postoperative Course ◽  
Common Complaint ◽  
Giant Pituitary Adenomas ◽  
The Mean ◽  
Prognostic Implications ◽  
Group 5 ◽  
Pituitary Macroadenomas

Abstract BACKGROUND In this study we compared giant pituitary adenomas (GPAs) and non-giant pituitary macroadenomas (nGPAs) on the basis of presenting complaints, surgical procedures, tumor resections and outcomes. METHODS A retrospective analysis (2006-2017) of pituitary macroadenomas was performed where tumors were divided into two groups; tumors greater than 4 cm were classified as GPAs while macroadenomas smaller than 4 cm were termed as nGPAs. Both GPA and nGPA had 75 patients in each group. RESULTS The most common complaint of all patients was visual deterioration (77.3% of patients with nGPAs and 89.3% of patients with GPAs). Visual field defects were present in 55 patients (73.3%) in the nGPA group compared to 68 patients (90.7%) in the GPA group (p=0.006). The mean volume of nGPAs was 6.3 cm3 (range 0.45 cm3 to 22 cm3 while the mean volume of GPAs was 30.1 cm3 (range 10.8 cm3 to149.4 cm3) (p=0.001). The mean extent of resection was 88.9% for nGPAs whereas the mean extent of resection was 76.7% for GPAs (p=0.03). Craniotomy was required only in the GPA group (5 patients, 6.7%) (p=0.023). Tumor recurrence/progression was seen in 9.3% of patients with nGPAs and 44% of patients with GPAs (p=&lt; 0.001). Re-do surgery was required in 2.7% of nGPA cases (via transsphenoidal approach) and 32% of GPA cases; in this GPA subgroup, 22.7% patients required transsphenoidal surgeries while 9.3% patients required transcranial surgeries. Stereotactic radiosurgery in recurrence/progression accounted for 4% of nGPA patients and 22.7% of GPA patients. There were 3 mortalities, all in GPA group. Overall, nGPA group had better postoperative course as compared to GPA group. CONCLUSION The frequency of preoperative symptoms in GPAs is more significant and associated with lesser chances of gross total tumor resection, higher rates of recurrence, and worse postoperative course in comparison to nGPAs.

Reformatted Sagittal Images in the Differential Diagnosis of Meningiomas and Pituitary Adenomas with Suprasellar Extension

Neurosurgery ◽  
1986 ◽  
Vol 18 (5) ◽  
pp. 555-558 ◽  
Author(s):  
Craig W. Clark ◽  
James D. Acker ◽  
Jon H. Robertson ◽  
Frank Eggers ◽  
Michael S. Muhlbauer
Keyword(s):  
Computed Tomography ◽  
Differential Diagnosis ◽  
Pituitary Adenoma ◽  
High Resolution ◽  
Pituitary Adenomas ◽  
Pituitary Tumors ◽  
Suprasellar Extension

Abstract Approximately 3 to 4 times a year, a tumor with suprasellar extension escapes classification on high resolution coronal and transaxial computed tomography. When arteriography failed to determine the diagnosis, the differential choices were usually meningioma or pituitary adenoma. The authors report the use of sagittal reformatted images in this differential diagnosis and conclude that these images may aid in the distinction between pituitary tumors with suprasellar extension and meningiomas located in this area.

Hybrid fluorescein-guided surgery for pituitary adenoma resection: a pilot study

2020 ◽  
Vol 132 (5) ◽  
pp. 1490-1498 ◽  
Author(s):  
Samuel Romano-Feinholz ◽  
Víctor Alcocer-Barradas ◽  
Alejandra Benítez-Gasca ◽  
Ernesto Martínez-de la Maza ◽  
Cristopher Valencia-Ramos ◽  
...  
Keyword(s):  
Pituitary Adenoma ◽  
Pilot Study ◽  
Pituitary Adenomas ◽  
Tumor Resection ◽  
Scar Tissue ◽  
Spectrophotometric Analysis ◽  
Guided Surgery ◽  
Yellow 560 ◽  
Acth Secreting ◽  
Microscopic Techniques

OBJECTIVEThe authors conducted a pilot study on hybrid fluorescein-guided surgery for pituitary adenoma resection and herein describe the feasibility and safety of this technique.METHODSIn this pilot study, the authors included all consecutive patients presenting with pituitary adenomas, functioning and nonfunctioning. They performed a hybrid fluorescein-guided surgical technique for tumor resection. An endonasal endoscopic approach was used; after exposure of the rostrum of the sphenoid sinus, they administered a bolus of 8 mg/kg of fluorescein sodium (FNa) intravenously, and during resection, they alternated between endoscopic and microscopic techniques to guide the resection under a YELLOW 560 filter.RESULTSThe study included 15 patients, 7 men (47%) and 8 women (53%). Of the pituitary adenomas, 7 (46%) were nonfunctioning, 6 (40%) were GH secreting, 1 (7%) was prolactin secreting, and 1 (7%) was ACTH secreting. There were no FNa-related complications (anaphylactic reactions); yellowish staining of urine, skin, and mucosa was seen in all patients and resolved in a maximum time of 24 hours. After color spectrophotometric analysis, the authors identified a statistical difference in fluorescence among tumor, gland, and scar tissue (p = 0.01).CONCLUSIONSThis is the first study of its kind to describe the feasibility and safety of using FNa to guide the resection of pituitary adenomas. The authors found this technique to be safe and feasible. It may be used to obtain better surgical results, especially for hormone-producing and recurring tumors, as well as for reducing the learning curve in pituitary adenoma surgery.

Sign in / Sign up

Export Citation Format

Share Document